Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
AssigneeAstraZeneca AB
InventorsOlle Korsgren, Bo Nilsson
Life of this patent
Estimating the term…
Abstract
According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.
Claims22
1-38. (canceled)
A method of treating Type I diabetes mellitus, which comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.
A method of improving insulin-independency in patients having Type I diabetes mellitus, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such improvement.
A method of treatment of instant blood-mediated inflammatory reaction, which method comprises administering a therapeutically-effective amount of melagatran, or a pharmaceutically-acceptable derivative thereof, to a patient in need of such treatment.
A kit of parts comprising components:
- (a) a first component comprising melagatran or a pharmaceutically-acceptable derivative thereof;
- and
- (b) a second component comprising cells,
- which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
Dependencies are inferred from the claim text.